These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. Monaco TJ; Davila CD Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200 [TBL] [Abstract][Full Text] [Related]
5. Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan. Tynan T; Hird K; Hannon T; Gabbay E J Int Med Res; 2019 May; 47(5):2177-2186. PubMed ID: 30975046 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198 [TBL] [Abstract][Full Text] [Related]
7. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats. Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082 [TBL] [Abstract][Full Text] [Related]
8. Macitentan (Opsumit) for pulmonary arterial hypertension. Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031 [No Abstract] [Full Text] [Related]
9. Macitentan for the treatment of pulmonary arterial hypertension. Spikes L; Williamson T; Satterwhite L Drugs Today (Barc); 2014 Jun; 50(6):401-6. PubMed ID: 24983588 [TBL] [Abstract][Full Text] [Related]
10. Macitentan in the treatment of pulmonary hypertension in Gaucher‚s disease. Taylan G; Aktoz M; Celik M; Yılmaztepe M Anatol J Cardiol; 2020 Jan; 23(2):114-116. PubMed ID: 32011319 [No Abstract] [Full Text] [Related]
11. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315 [TBL] [Abstract][Full Text] [Related]
12. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension. Krause A; Zisowsky J; Dingemanse J Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590 [TBL] [Abstract][Full Text] [Related]
13. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension]. Avdeev SN Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621 [TBL] [Abstract][Full Text] [Related]
14. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. Herbert S; Gin-Sing W; Howard L; Tulloh RMR Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. Sidharta PN; Krähenbühl S; Dingemanse J Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973 [TBL] [Abstract][Full Text] [Related]
16. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Mehta S; Sastry BKS; Souza R; Torbicki A; Ghofrani HA; Channick RN; Delcroix M; Pulido T; Simonneau G; Wlodarczyk J; Rubin LJ; Jansa P; Hunsche E; Galiè N; Perchenet L; Sitbon O Chest; 2017 Jan; 151(1):106-118. PubMed ID: 27671974 [TBL] [Abstract][Full Text] [Related]
17. Serious Liver Injury Associated with Macitentan: A Case Report. Tran TT; Brinker AD; Muñoz M Pharmacotherapy; 2018 Feb; 38(2):e22-e24. PubMed ID: 29286546 [TBL] [Abstract][Full Text] [Related]
18. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Vachiéry JL; Delcroix M; Al-Hiti H; Efficace M; Hutyra M; Lack G; Papadakis K; Rubin LJ Eur Respir J; 2018 Feb; 51(2):. PubMed ID: 29437943 [TBL] [Abstract][Full Text] [Related]
19. Macitentan for the treatment of pulmonary arterial hypertension. Kholdani CA; Fares WH; Trow TK Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]